Abstract
In 1997, Grabowski and Mullins described why pharmacy benefit management use of pharmacoeconomics was limited. The current manuscript examines recent changes in health care payers’ use of pharmacoeconomic information, payers’ perceptions of that information’s value for informing formulary decision making, and payers’ attitudes toward the generation and dissemination of pharmacoeconomic evidence. Despite a perceived improvement in the scientific rigor and “real-world applicability” of pharmacoeconomic information, payers remain skeptical of pharmacoeconomic evidence generated or funded by pharmaceutical manufacturers. This skepticism is reinforced when transparency is limited and when the picture provided of the comparative effectiveness of alternative products is incomplete. Payers suggest that greater two-way communications between payers and drug manufacturers could improve the usefulness of pharmacoeconomic information.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of the Economics of Business
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
